Loading...
XNYSAVTR
Market cap14bUSD
Dec 31, Last price  
21.07USD
1D
-0.05%
1Q
-17.50%
IPO
36.73%
Name

Avantor Inc

Chart & Performance

D1W1MN
XNYS:AVTR chart
P/E
44.66
P/S
2.06
EPS
0.47
Div Yield, %
0.00%
Shrs. gr., 5y
6.44%
Rev. gr., 5y
3.51%
Revenues
6.97b
-7.26%
4,909,600,000636,900,000691,300,0001,247,400,0005,864,300,0006,040,300,0006,393,600,0007,386,100,0007,512,400,0006,967,200,000
Net income
321m
-53.23%
686,500,00021,600,000-42,400,000-112,700,000-86,900,00037,800,000116,600,000572,600,000686,500,000321,100,000
CFO
870m
+3.13%
843,600,000124,600,00072,900,000-167,500,000200,500,000354,000,000929,800,000953,600,000843,600,000870,000,000
Earnings
Feb 12, 2025

Profile

Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
URL
https://www.avantorsciences.com/
IPO date
May 17, 2019
Employees
14,500
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
6,967,200
-7.26%
7,512,400
1.71%
Cost of revenue
4,603,400
4,909,600
Unusual Expense (Income)
NOPBT
2,363,800
2,602,800
NOPBT Margin
33.93%
34.65%
Operating Taxes
89,400
164,600
Tax Rate
3.78%
6.32%
NOPAT
2,274,400
2,438,200
Net income
321,100
-53.23%
686,500
19.89%
Dividends
(32,400)
Dividend yield
0.23%
Proceeds from repurchase of equity
(13,700)
4,100
BB yield
0.09%
-0.03%
Debt
Debt current
259,900
364,200
Long-term debt
5,516,500
6,074,600
Deferred revenue
Other long-term liabilities
261,800
295,400
Net debt
5,463,400
5,999,200
Cash flow
Cash from operating activities
870,000
843,600
CAPEX
(146,400)
(133,400)
Cash from investing activities
(143,700)
(109,600)
Cash from financing activities
(843,700)
(648,700)
FCF
2,232,000
2,196,200
Balance
Cash
262,900
372,900
Long term investments
50,100
66,700
Excess cash
63,980
Stockholders' equity
5,252,600
4,855,400
Invested Capital
11,139,500
11,374,320
ROIC
20.20%
21.25%
ROCE
20.11%
21.39%
EV
Common stock shares outstanding
678,400
679,400
Price
22.83
8.25%
21.09
-49.95%
Market cap
15,487,872
8.09%
14,328,546
-43.29%
EV
20,951,272
20,327,746
EBITDA
2,766,100
3,008,300
EV/EBITDA
7.57
6.76
Interest
284,800
265,800
Interest/NOPBT
12.05%
10.21%